Measles virus (MV)-PNP H blind antiCD20 is a CD20-targeted and prodrug convertase-armed MV that temporarily controls growth of lymphoma xenografts in severe combined immunodeficiency (SCID) mice in combination with fludarabine phosphate (fludarabine). Herein, we examine the replication of this targeted virus and of a vaccine-lineage MV in disease bulks and circulating cells from mantle cell lymphoma (MCL) patients, and show that only the targeted virus is specific for CD20-expressing cells. We then assessed the efficacy of different regimens of administration of this virus in combination with fludarabine and cyclophosphamide (CPA) in an MCL xenograft model. We show that CPA administration before the beginning of virus treatment enhances oncolytic efficacy, likely through temporary immunosuppression.
Introduction
Most therapeutic regimens for lymphoma are based on combinations of drugs, radiation and/or surgery to maximize patient survival. Oncolytic viruses are also being combined with other therapeutic modalities: the genetically modified adenovirus H101, which is approved in China for the treatment of head and neck carcinoma, is delivered in combination with chemotherapy. 1 Moreover, several current clinical trials are based on the combination of oncolytic viruses with other therapies. 2, 3 However, current combination regimens rarely achieve synergy between virus and chemotherapy. 4 To maximize the therapeutic potential, we sought to reprogram a measles virus (MV) into an oncolytic virus capable of targeting, and enhancing the effects of different chemotherapeutics approved for treatment of lymphoma.
We reasoned that MV might be especially adept to treat lymphoma because of its natural tropism for lymphocytes. 5 Indeed, spontaneous lymphoma 6 and leukemia 7 regressions were repeatedly observed after wild-type MV infection. Moreover, a phase I study of intratumoral injections of the unmodified MV Edmonston-Zagreb vaccine strain in patients with cutaneous T-cell lymphomas showed safety as well as clinical responses. 8 Pre-clinical studies based on human lymphoma xenografts in immunodeficient mice, treated with a vaccine strain MV, confirmed strong oncolytic effects. 9 A first-line treatment for selected non-Hodgkin's lymphoma, as well as a salvage regimen in mantle cell lymphoma (MCL), [10] [11] [12] [13] is a combination of fludarabine phosphate (fludarabine), cyclophosphamide (CPA) and the CD20 antibody rituximab (FCR) regimen. To improve on FCR efficacy, we generated MV-purine nucleoside phosphorylase (PNP) H blind antiCD20, 14 a virus targeted to CD20-expressing cells, blinded to the natural receptors and armed with the prodrug convertase Escherichia coli PNP. For infectivity studies, we also generated a similar virus expressing green fluorescent protein (GFP) in place of PNP, and named it MV-GFP H blind antiCD20. 14 Initially, we characterized how the PNP-expressing virus interacts in vitro and in vivo with fludarabine. 14 Virus-expressed PNP locally activates fludarabine to 2-fluoroadenine, a highly diffusible substance that is metabolized to toxic adenosine triphosphate analogs capable of inhibiting DNA, RNA and/or protein synthesis immediately. 15 In conventional therapy (in the absence of E. coli PNP), fludarabine is not metabolized efficiently to 2-fluoroadenine, and thus is not as effective. We previously characterized parameters for the safe application of MV-PNP H blind antiCD20 in combination with fludarabine, in genetically modified mice, susceptible to MV infection and showed that virus plus fludarabine temporarily control growth of Burkitt (Raji cells) and MCL (Granta cells) lymphoma xenografts in severe combined immunodeficiency (SCID) mice. 14 Herein, we compared the replication of the CD20targeted and vaccine-lineage MV in primary lymphoma cells from MCL patients, and showed that only the targeted virus is strongly specific for CD20-expressing lymphoma cells. In anticipation of moving toward a phase I clinical trial, we also sought to treat MCL xenografts established in SCID mice. We administered CPA before the beginning of virus treatment to establish immunosuppression and enhance virus replication, resulting in increased oncolytic efficacy. We then optimized the dosing and scheduling for CPA, MV-PNP H blind antiCD20 and fludarabine, and defined the interval between virus and fludarabine application that produced the strongest oncolytic effect. Different types of cyclic treatments were also tested, one of which more than tripled the survival time.
Results

CD20-targeting of MV to primary lymphoma cells of MCL patients
To assess in clinical samples the level of specificity conferred to MV by targeting to CD20, we used tumor biopsies or peripheral blood mononuclear cells (PBMCs), including circulating lymphoma cells, from MCL patients. These samples were divided into aliquots that were infected either with the GFP-expressing virus MV-GFP H blind antiCD20 14 or with a control vaccinelineage virus with the same CD46 receptor specificity of the MV, currently used in clinical trials, 16, 17 or were mock infected. Figure 1 shows an analysis of the levels of infection of CD20-positive and CD20-negative PBMCs from three patients. At a multiplicity of infection of 1, the vaccinelineage MV (MV-GFP) efficiently infected both cell populations of all three patients (28-65% infected cells, Figures 1a-c, right upper and lower panels). At the same multiplicity of infection, MV-GFP H blind antiCD20 infected about 30% of the CD20-positive cells of patients A and B, but only about 4 and 7% of the CD20-negative cells of these patients, respectively (Figure 1a , second from the right panels, and Figure 1b , left panels). Thus, CD20-expressing cells of patients A and B were infected approximately seven and five times more efficiently than the CD20-negative cells. However, the ratio of infection of the CD20-positive and CD20-negative cells of patient C was close to 1 (Figure 1c , compare the left and right pairs of panels). Thus, we carried out additional comparative infection analyses in PBMCs or in spleen biopsy samples from eight different MCL patients. Analyses of these samples confirmed the heterogeneity of specific infection ratios: about four-to sixfold preferential infection was documented in samples from three patients, twofold preferential infection in other three samples, and no specificity in two samples. Five times higher multiplicity of infection enhanced the percentile of infected cells 1.5 to 5 times but did not alter infection ratios (data not shown). Thus, two-to sevenfold enhanced CD20 specificity of the retargeted virus was documented in 8 of 11 patients' samples.
Systemic treatment with virus and fludarabine reduces primary tumor burden
We previously documented that intratumoral inoculation of the PNP-armed version of the CD20-targeted virus (MV-PNP H blind antiCD20) is effective in the treatment of Granta 519 MCL xenografts in SCID mice. 14 As intratumoral therapy is of limited value for the treatment of a disseminated malignancy like MCL, we injected the virus through tail vein with or without subsequent intraperitoneal fludarabine administration. We assessed oncolytic efficacy of systemic virus administration by measuring the volume of subcutaneously implanted xenografts over time.
As in our previous study, treatment started when subcutaneous MCL tumors reached an average volume of 20-40 ml. Groups of nine mice were treated with virus alone (five doses in consecutive days), fludarabine alone (three doses in consecutive days), a combination of virus and fludarabine (first dose of fludarabine administered one day after the last dose of virus) or left untreated (mock treatment). The means of the tumor volumes in each group of mice measured every third day over a 27day period are shown in Figure 2a . The tumor volumes in individual mice at day 24 post-treatment are shown in Figure 2b .
As expected, fludarabine had a small but significant therapeutic effect; a moderate reduction of tumor volume was documented in the fludarabine-only treated mice compared with the mock-treated group ( The tumor volumes measured in individual mice 27 days after the start of treatment were as follows: all but one of the nine mock-treated mice had been killed due to tumor burden (41700 ml). Seven of the nine mice treated with fludarabine had tumors ranging in size from 787 to 1690 ml, one was killed, and one tumor regressed. Seven of eight mice treated with virus alone had tumors ranging in size from 256 to 1267 ml, and one tumor regressed. Five of nine combination-treated mice had tumors ranging in size from 48 to 600 ml, with four tumor regressions. Altogether, these data show that intravenous (i.v.) treatment with virus, followed by fludarabine administration, is effective in initially reducing the primary tumor volume. However, the xenografts eventually resumed growing.
Fludarabine administration 1 week after virus delivery is most effective
The timing of prodrug administration after i.v. virus delivery can be critical, as previously documented for an Virally enhanced chemotherapy of mantle cell lymphoma G Ungerechts et al armed adenovirus. 18 In an empirical attempt to synchronize prodrug delivery with high levels of virus replication, we extended the time window between virus inoculation and fludarabine delivery. In another experiment, the first treatment group received fludarabine on days 5, 6 and 7 after the first virus administration (Figure 3a , open circles, group F1 timing), as done in our initial experiment. The second and third treatment groups received fludarabine at days 12, 13 and 14 after the first virus administration (Figure 3a , open squares, group F2 timing) or at days 19, 20 and 21 thereafter (Figure 3a , open diamonds, group F3 timing). Maximum efficiency of oncolysis was achieved with the schedule F2: two-sample t-test of pair-wise comparison of this group of mice with the MV-only group on day 15 yielded a significant value of P ¼ 0.02. The F1-MV-only comparison and F3-MV-only comparison yielded the non-significant values of P ¼ 0.14 and P ¼ 0.6, respectively. Accordingly, all mice in the F2 treatment group were alive 33 days post tumor implantation ( Figure 3b , open squares), while most mice in the F1 and F2 treatment groups had already been killed. Thus, we selected the 1-week time interval for fludarabine administration in subsequent experiments.
CPA administration 1 day before infection improves oncolytic efficacy
CPA is a component of the FCR regimen, but it is also an immunosuppressant that acts on both acquired and innate immunity. We and others have previously taken advantage of the immunosuppressive property of CPA to Figure 1 Selective entry of a CD20-targeted measles virus (MV) in lymphoma cells from mantle cell lymphoma (MCL) patients. Peripheral blood mononuclear cells (PBMCs), including lymphoma cells, from three MCL patients (a-c) were infected with the CD20-targeted virus (MV-GFP H blind antiCD20), the control virus with ubiquitous entry (MV-GFP) or left uninfected (shown only for patient A, left set of panels). Two days after infection, CD45-positive live cells were gated, and among these cells, CD20-positive and CD20-negative populations were identified (vertical axis). In each cell population, the percentile of green fluorescent protein-expressing cells was determined (horizontal axis).
Virally enhanced chemotherapy of mantle cell lymphoma G Ungerechts et al enhance MV replication in toxicity, 19 and efficacy 20 studies of oncolytic therapy in immunocompetent models. CPA was also shown to inhibit the innate immune response in oncolysis protocols using other viruses. 21, 22 We therefore assessed whether administration of a single dose of CPA enhances oncolytic efficacy in the SCID xenograft model, in which acquired immune responses are minimal. To limit the direct anti-tumor effects of the cytoreductive agent CPA, which occur through DNA alkylation, we treated mice bearing subcutaneous MCL xenografts with doses of 25, 50 or 100 mg CPA kg À1 . Figure 4a shows the time course of tumor growth in different experimental groups, and Figure 4b shows the tumor volumes in individual mice 18 days after CPA administration. Treatment with 25 mg kg À1 (Figures 4a and b , triangles) had no effect on tumor growth, producing an overlapping growth curve with the negative control ( Figures 4a and b , mock, squares). Treatment with 50 mg kg À1 (Figures 4a and b , dots) had a limited effect on tumor growth that was not significant (P ¼ 0.0551 compared with mock treatment), whereas treatment with 100 mg kg À1 retarded tumor growth significantly (Figures 4a and b, diamonds; P ¼ 0.0019 compared with mock treatment). As our goal was to limit the direct anti-tumor effect of CPA, allowing potential effects of virus therapy to manifest, the intermediate dose (50 mg kg À1 ) was selected for subsequent experiments.
Triple-treatment chemovirotherapy: CPA, virus and fludarabine
We then assessed the efficacy of a triple treatment regimen for MCL, combining the clinically approved components CPA and fludarabine with our armed and targeted virus. We used the optimal concentration and timing parameters, determined in the experiments above: a single intraperitoneal injection of CPA (50 mg kg À1 ), or control saline at day À1 followed by five i.v. injections of 10 6 infectious units of virus, or mock-infection, at days 0-4. Groups of mice treated with The kinetic analysis of tumor growth was done in groups of 10-12 mice and is shown in Figure 5a . Tumor volume data from all individual mice in each group are shown in Figure 5b at day 20 after start of viral treatment. CPA application alone (filled triangles) only marginally slowed tumor growth as compared with saline (filled squares), and this effect occurred in the initial days of treatment. Treatment with virus alone (filled circles) retarded tumor growth more markedly, and this effect was evident 10 days after virus application, suggesting an important role for virus replication. Treatment with virus and CPA (open triangles) appeared to be initially more effective than treatment with either individual component, and was significantly different from treatment with virus alone on day 20 of the experiment (P ¼ 0.0177, Figure 5b ). Treatment with virus and fludarabine (open circles) seemed to be slightly more effective than treatment with virus and CPA, and tumor volume on day 20 was significantly lower (P ¼ 0.0077, Figure 5b ). Finally, the combination of all three therapeutics (open squares) reduced tumor burden Virally enhanced chemotherapy of mantle cell lymphoma G Ungerechts et al significantly better than any other treatment (day 20, P ¼ 0.0002 as compared with virus alone). However, a single round of this combination therapy did not eliminate the tumor. The percentile of tumor cells circulating in the blood of mice on day 25 was also examined systematically as a second parameter of treatment efficacy. Remarkably, a significant decrease in circulating MCL cells was seen in all virus-treated mice when compared with mock-treated animals (Figure 5c ). Although PBMCs of mock-treated mice averaged approximately 11% tumor cells (left column), only very few (about 1% or less) tumor cells were detected in the blood of virus-treated animals (third to sixth column). Thus, virus treatment was particularly effective at reducing the number of circulating tumor cells.
Repeated sequential treatment with CPA, virus and fludarabine eliminates implanted tumors and prolongs survival
In clinical practice, lymphoma therapy is typically based on sequential administration of multiple cycles of therapy. To obtain in vivo data towards a clinical trial for the treatment of MCL patients, we compared the effect of different schedules of sequential delivery of virus and chemotherapeutics on the growth of MCL tumors in SCID mice. Figure 6a Figure 6b , compare triangles with circles), but was unable to completely control tumor growth. Nine of the 11 mice treated had to be killed 38-47 days after the beginning of treatment, whereas all 10 untreated mice had to be killed at days 20-26 (average survival: 23 days). The triple+2F treatment (Figures 6a and b , diamonds; average survival: 51.5 days) slowed tumor growth and extended survival slightly more efficiently than the triple treatment.
The triple-triple treatment was clearly most effective: a few days after the second cycle of virus delivery, tumor growth slowed and was controlled (Figure 6a, squares) . Statistical analysis carried out in the third month of treatment indicated highly significant tumor volume differences between this and the other treatments (P ¼ 0.0004 compared with triple treatment; P ¼ 0.0038 compared with triple+2F). Simultaneously with the third cycle of virus delivery, the volumes of most tumors began to shrink. However, while the subcutaneously implanted tumors were disappearing, several mice developed complications and all mice had to be killed at days 70-80 (average survival: 77 days, Figure 6b , squares).
Causes of morbidity and mortality
The symptoms noted in individual mice in all four experimental groups are listed in the three left columns of Table 1 ; pathological findings at autopsy are listed in the four columns on the right. Several mice showed signs of systemic disease, including wasting, leg paralysis, ascites, labored breathing, a hunched posture and body tremors. These symptoms were detected only in the treatment groups because all non-treated animals had to be killed early. With one exception, symptoms started after day 35, and 13 of 17 symptom-related deaths were after day 49. On necropsy therapy-refractory tumors were diagnosed in the abdomen and/or thorax or in inguinal and axillary lymph nodes. Spleens were enlarged in all treatment groups except group three, which had the smallest implanted tumor weights, the lowest average increase in lymph node weight, but also the largest increase in the weight of new Figure 6 Repeated sequential chemovirotherapy leads to complete regression of implanted tumors and long-term survival. (a) Time course of tumor growth in mice treated with different regimens of three therapeutics. Groups of about 12 mice were treated, but fatalities due to repeated injections caused some losses in each group, as detailed in Table 1 . The schedule of each treatment is indicated below the time axis. (b) Kaplan-Meier survival curves. Symbols are as in (a). The defined end point was 1700 ml of tumor volume. After day 52, no mice had to be killed because of excessive tumor volume. Abbreviations: C, CPA; F, fludarabine; MV, measles virus.
Virally enhanced chemotherapy of mantle cell lymphoma G Ungerechts et al therapy-resistant tumors. These observations suggest that implanted tumors, but not secondary tumors, were well controlled by therapy. To assess whether secondary tumors had reduced CD20 expression levels, tumors were analyzed by immunohistochemistry, but there were no obvious differences in the levels of expression between the primary and secondary tumors.
To assess whether tumor cells were circulating during early and late phases of infection, blood smears were done at day 21, and then again at autopsy. The day 21 analyses showed that the mock-treated group averaged about 10% circulating tumor cells in the PBMCs, whereas the three treatment groups all averaged only 1-2% circulating tumor cells (1.8, 1.4 and 1.4% for groups 1, 2 and 3, respectively, data not shown). At the time of necropsy, however, average percentage of tumor cells in PBMCs in experimental groups was in the same range as in the non-treated group. Thus, the three complete cycles of chemotherapy and virus treatment often resulted in complete elimination of the implanted tumor, but failed to control secondary tumors and circulating MCL cells.
Discussion
Targeting efficacy in clinical samples
Translation of promising results from the bench to the bedside is challenging, and the excitement of providing new therapies for otherwise incurable cancer is often countered by loss of efficacy in vivo, and safety concerns. Targeting has great potential for enhancing safety and potency of new therapeutic modalities, but its efficacy must be proven in patients' materials and in animal systems. We show here that a vaccine-lineage MV with CD46 receptor specificity infects spleen disease bulks and PBMCs of MCL patients with roughly the same efficiency as it infects the stable cell lines used to propagate it. However, this virus infects with similar efficiency the CD20-expressing lymphoma cells and non CD20-expressing normal immune cell types, including T-lymphocytes.
In contrast, MV-PNP H blind antiCD20 shows enhanced specificity for CD20-expressing cells from MCL patients, infecting CD20-positive lymphoma cells 2-7 times more efficiently than the CD20-negative cells. This level of specificity is less pronounced in lymphoma cells than in PBMCs of healthy individuals, where we measured a tenfold higher infectivity in CD20-positive than in CD20-negative cells (K-CY, MF and RC, unpublished), or than in cultivated cells, where 40-to 100-fold specificity gains have been documented. 23, 24 Even if by the above criteria, the two-to seven fold gain in specific cell entry and viral replication documented here in most clinical samples seems small, this gain can be of critical importance. However, complete lack of CD20-specificity in clinical samples of three of the 11 patients was also documented. This was unexpected, and is not yet understood, but may be due to complicating variables such as therapy received before obtaining patient samples. These data argue for comparing the replication of MV-PNP H blind antiCD20 and vaccine-lineage MV in individual samples, before considering inclusion of a patient in a MCL clinical trial based on a retargeted therapeutic virus. Enlarged spleen is defined as >175% of the weight of age-matched normal SCID mice.
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Delivery schedule
In addition to quantifying targeting efficiency in clinical samples, we sought to develop an effective pre-clinical protocol for timing the delivery of MV-PNP H blind antiCD20 in combination with fludarabine and CPA. Combination therapies with oncolytic viruses requires accurate timing because viruses need to replicate in target cells before developing their full synergistic potential with chemotherapeutics. Viruses armed with convertases that toxify a substrate can poison the host cell suddenly, thus effectively arresting the viral spread. We previously characterized parameters for the safe application of MV-PNP H blind antiCD20 in combination with only fludarabine in genetically-modified mice susceptible to MV infection. 14 The sequence and timing of administration and dosage of these three components was planned based on the results from previous experimentation with MV and other oncolytic viruses. [20] [21] [22] We reasoned that the appropriate sequence was administration of CPA, followed by administration of the virus, and finally the administration of fludarabine. Indeed, a single CPA dose applied intraperitoneally 1 day before the beginning of the i.v. virus treatment, enhanced its oncolytic efficacy, likely by suppressing host's innate and adaptive immunity, and favoring virus replication, as observed with other oncolytic viruses. [25] [26] [27] We then optimized the time window between application of virus and fludarabine treatment: the initial empirical treatment schedule was based on fludarabine administration 1 day after the last virus dose, 14 but a study with an armed adenovirus 18 showed that increasing the interval time between infection and prodrug administration, improved therapeutic efficacy. Here, we show that the most effective time point for fludarabine administration was 1 week after the last virus injection. Thus, the optimal sequence of delivery is CPA on day À1, virus on days 0-4 and fludarabine on days 12-14. The third improvement was repetition of the 23-day course of sequential treatment with CPA, virus and fludarabine; consistently three repetitions of the treatment caused complete regression of the implanted tumors.
Proposed MCL clinical trial
Our data compare favorably with pre-clinical studies of a reagent currently in phase 1 clinical trials, that is, the therapeutic HLA-DR-specific monoclonal antibody 1D09C3. 28 Repeated i.v. administration of this antibody to SCID mice with implanted Granta 519 cell xenografts, was less effective than the above described treatment regimen, including CPA, virus and fludarabine. In the experiments dealing with 1D09C3, long-term survival at day 50 after tumor implantation was only 80% and there was no complete remission within the observation period of 46 days. A further pre-clinical study with MCL-bearing SCID mice showed synergistic effects of the proteasome inhibitor bortezomib, the anti-CD20 antibody rituximab and CPA with a therapeutic outcome similar to that described in our study with a 70% longterm survival at day 70 after tumor implantation and complete remission of subcutaneous tumors. 29 Thus, our pre-clinical efficacy data supports the development of a clinical protocol, especially when it is noted that the side-effects that interfered with survival in our animal models can often be successfully controlled in patients.
We are designing a phase I clinical trial to test the safety of MV-PNP H blind antiCD20 in combination with fludarabine and CPA, to be named FCV for fludarabine, CPA and virus. MCL patients who fail chemo-and radiation therapy will be recruited. The new salvage regimen will be on the basis of the sequence and timing of delivery of the reagents tested in the above pre-clinical experiments. Current FCR clinical regimens administer rituximab (375 mg m À2 ) on day 1, cyclophosphamide (250 mg m À2 ) and fludarabine (25 mg m À2 ) on days 2-4. The cycle is completed by 24 days of rest and is repeated up to six times. A comparable FCV course would consist of a single administration of cyclophosphamide (375 mg m À2 , half the total dose administered over 3 days in the FCR regimen) on day 1, administration of the virus in a dominant node on day 2, 1 week of rest, fludarabine administration (25 mg m À2 ) on days 10-12, and 2 weeks of rest. This course will be repeated up to six times. We are aware of the possible toxic effects of these combination treatments; as slow leukocyte and platelet recovery often necessitate delays in administration and dose reductions in the FCR regimen, we would propose a stepwise reduction in fludarabine in response to toxicity. Side-effects in a clinical trial based on the FCV regimen may be aided by experience gained from patients treated with the FCR regimen. 30 Systemic treatment of patients with high MV-neutralizing antibodies titers remains a challenge. Two MV-based clinical trials currently open (ovarian carcinoma and glioma), depend on the local virus administration, and a third trial using systemic delivery treats myeloma patients with low titers of MV antibodies. 31 Even when no antibodies are present, the first injection of an oncolytic virus will induce neutralizing antibodies that can quench the activity of subsequent injections. To avoid neutralization, other viral systems have used the envelopes of different serotypes and are used sequentially. 32 As recoating with alternative serotypes is not possible for MV, which is monotypic in nature, we have used the envelope proteins of canine distemper virus to shield MV from neutralizing antibodies (K-CY, J Lampe, GU and RC, unpublished data), and vice-versa. 33 Moreover, we are generating a chimeric virus with the retargeted envelope glycoproteins of another paramyxovirus. 34 Thus, retargeted viruses capable of escaping neutralization may soon be available for more effective consecutive cycles of systemic therapies.
Materials and methods
Viruses
Two CD20-targeted MV, one armed with PNP and named MV-PNP H blind antiCD20, the other expressing GFP from the same additional transcription unit and named MV-GFP H blind antiCD20, were previously generated in our laboratory. 14 To prepare stocks, Vero-aHis cells 35 were infected (multiplicity of infection of 0.03) and incubated at 37 1C for 36 h. Virus was harvested by one freeze-thaw cycle and resuspended in Opti-MEM (Invitrogen, Grand Island, NY, USA). Titers were determined by 50% tissue culture infectious dose titration by the method of Kärber 36 on Vero-aHis cells. Primary MCL cells were recovered from fresh blood or surgically removed spleen tissue. When cells were recovered from spleen, fresh tissue was cut up, and minced over an 80-mm wire mesh to obtain a single cell suspension, which was overlaid on Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ, USA) and centrifuged to isolate the mononuclear cell layer. Fresh whole blood was collected in EDTA tubes (BD Biosience, San Jose, CA, USA) and subjected to Ficoll-Hypaque (GE Healthcare) density gradient centrifugation, as above. The cell layer was then collected, washed twice with Hank's buffered saline solution (Mediatech, Manassas, VA, USA), counted, and 5 Â 10 4 cells per well were seeded on a 24-well plate in RPMI 1640 (Mediatech) supplemented with 10% fetal calf serum and antibiotics.
Infection of patient's materials and flow cytometry analyses
The cells were then infected at a multiplicity of infection of 1 (5 Â 10 4 50% tissue culture infectious dose) with either MV-GFP H blind antiCD20 14 or MV-GFP (also named MV green ). 37 Forty-eight hours after infection, cells were harvested and washed twice with washing buffer: 5% fetal calf serum, 0.05% sodium azide in phosphatebuffered saline. Cells were labeled using PE CD20 (BD Bioscience; 10 ml per test; catalog number (cat): 555623), PerCP CD45 (BD Bioscience; 5 ml per test; cat: 340665) and in some cases APC CD3 (BD Bioscience; 15 ml per test; cat: 557597), for 1.5 h in the dark at 4 1C. The respective isotype controls were also included in every test, along with mock-infected cells. Cells were then washed twice with washing buffer, followed by a final wash with 5% fetal calf serum in phosphatebuffered saline and fixed in 1% paraformaldehyde in phosphate-buffered saline before carrying out fluorescence-activated cell sorting (FACS) analysis (FACSCalibur, BD Biosciences).
Compensation with single tube color was done on each sample in duplicate before each test run. A total of 10 000 events were acquired and analyzed using FACS-Diva software (BD Bioscience). Live CD45+ lymphocytes were gated according to the forward and side scatter properties. The CD45+ population was further gated for CD20+ and CD20À populations, and GFP signal within each population was used to determine virus infectivity in each sub-population. The mean CD20 fluorescence intensity was determined on patient's samples, but there was no correlation with levels of infection.
Cell culture
MCL cells (Granta 519) 38 and Vero-aHis cells 35 were grown at 37 1C in a humidified atmosphere of 5% CO 2 either in RPMI with 10% fetal calf serum (Invitrogen) or in Dulbecco's modified Eagle's medium (DMEM) (Mediatech, Herndon, VA, USA) with 10% fetal calf serum, respectively.
Establishment of subcutaneous tumors
Experimental protocols were approved by the Institutional Animal Care and Use Committee. Tumors were established by inoculating Granta 519 cells (10 7 per 100 ml per site) subcutaneously into the right flanks of 6-8-week-old SCID mice (Harlan Laboratories Inc, Indianapolis, IN, USA).
Tumor treatment with virus, fludarabine or CPA When tumors measured an average of 20-40 ml, the treatment regimens were initiated. Virus (MV-PNP H blind antiCD20) was injected in the tail vein at 1 Â 10 6 infectious units in 100 ml Opti-MEM per dose for five consecutive days. Control animals were injected IV with equal volumes of Opti-MEM containing no virus. Intratumoral injections were as described. 14 Fludarabine phosphate for injection (SICOR Pharmaceuticals, Irvine, CA, USA) was reconstituted with sterile H 2 O as per the manufacturer's instructions. Mice receiving fludarabine were injected with 250 mg per kg body weight per dose intraperitoneally each day for 3 consecutive days.
CPA (Cytoxan for injection; Bristol-Myers Squibb, Princeton, NJ, USA) was reconstituted with sterile H 2 O, as per the manufacturer's instructions. When tumors measured an average of 20-40 ml, mice were treated with a single intraperitoneal injection of saline or CPA (25, 50 or 100 mg per kg body weight).
Measurements of tumor volume
Tumor diameters were measured every third day and the estimated volume (0.5 Â longest diameter Â width 2 ), was indicated as mean ± s.e.m. for each group. Animals were killed when their tumor burden reached a volume of about 10% of body weight (about 1700 ml). Treatment of the mice was halted if they lost 15% of their body weight, or if they developed severe symptoms of distress.
Blood collection from mice, and analysis
Samples of blood (50-200 ml) were taken by cheek bleed and collected in lithium heparin tubes (BD Bioscience). Most samples were analyzed by microscopy. Blood smears were prepared and stained with Wright-Giemsa (Sigma-Aldrich, St Louis, MO, USA) (as per the manufacturer's instructions). Standard differential white blood cell counts were done and slides were examined for the presence of circulating Granta 519 cells. The percentage of Granta 519 cells per total white blood cell was determined. In addition, some samples were analyzed by FACS. A phycoerythrin-labeled anti-human CD19 antibody and a phycoerythrin-labeled isotype control (BD Biosciences) were used. Flow cytometric analysis was done using FACSCalibur with Cell Quest software (BD Bioscience).
Complications
Mice receiving repeated cycles of treatments with CPA, virus and fludarabine often cleared the implanted tumors, but presented disseminated tumors and secondary disease signs. These included leg paralysis (an inability to extend or contract a leg-usually occurring with the rear legs), ascites (fluid in the abdominal cavity-usually noted by abdominal extension), hunched posture (a relatively inactive state in which the animal is in a fixed position with a highly arched back), wasting Virally enhanced chemotherapy of mantle cell lymphoma G Ungerechts et al (visible loss of body fat and muscle mass-actual weight loss may be masked by increased tumor volume), body tremors (mice display twitching or jerking motions, particularly in the upper half of the body) and labored breathing (mice are less active, appear to have strained breaths and prominent heartbeats).
Necropsies
For necropsies, tissues were collected in 10% (w/v) buffered formalin (Fisher Scientific, Kalamazoo, MI, USA). Sections of tissue were embedded in paraffin, cut, and stained with hematoxylin and eosin.
Statistical analyses
Data were analyzed by using the ANOVA test to compare the treatment groups for tumor volume analysis. The two-sample t-test was used to make pair-wise comparisons between the treatment groups. Survival data were analyzed by the Kaplan-Meier method and the log-rank test was used to test for significance between all the groups. As only mice that were killed due to maximum tumor volume were analyzed, the two-sample t-test was also used to make pair-wise comparisons between the groups. P-values o0.05 were considered statistically significant.
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